A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma

Research output: Contribution to journalJournal articlepeer-review

Standard

A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma. / Wu, Xiao; Yu, Wenfeng; Petersen, R. H.; Sheng, Hongxu; Wang, Yiqing; Lv, Wang; Hu, Jian.

In: BMC Cancer, Vol. 20, 429, 2020.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Wu, X, Yu, W, Petersen, RH, Sheng, H, Wang, Y, Lv, W & Hu, J 2020, 'A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma', BMC Cancer, vol. 20, 429. https://doi.org/10.1186/s12885-020-06927-w

APA

Wu, X., Yu, W., Petersen, R. H., Sheng, H., Wang, Y., Lv, W., & Hu, J. (2020). A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma. BMC Cancer, 20, [429]. https://doi.org/10.1186/s12885-020-06927-w

Vancouver

Wu X, Yu W, Petersen RH, Sheng H, Wang Y, Lv W et al. A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma. BMC Cancer. 2020;20. 429. https://doi.org/10.1186/s12885-020-06927-w

Author

Wu, Xiao ; Yu, Wenfeng ; Petersen, R. H. ; Sheng, Hongxu ; Wang, Yiqing ; Lv, Wang ; Hu, Jian. / A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma. In: BMC Cancer. 2020 ; Vol. 20.

Bibtex

@article{d80922f91d164d8290e7cf823d83fca7,
title = "A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma",
abstract = "BACKGROUND: Adenosquamous carcinoma (ASC) is an uncommon histological subtype of lung cancer. The purpose of this study was to assess the cumulative incidences of lung cancer-specific mortality (LC-SM) and other cause-specific mortality (OCSM) in lung ASC patients, and construct a corresponding competing risk nomogram for LC-SM.METHODS: Data on 2705 patients with first primary lung ASC histologically diagnosed between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The cumulative incidence function (CIF) was utilized to calculate the 3-year and 5-year probabilities of LC-SM and OCSM, and a competing risk model was built. Based on the model, we developed a competing risk nomogram to predict the 3-year and 5-year cumulative probabilities of LC-SM and the corresponding concordance indexes (C-indexes) and calibration curves were derived to assess the model performance. To evaluate the clinical usefulness of the nomogram, decision curve analysis (DCA) was conducted. Furthermore, patients were categorized into three groups according to the tertile values of the nomogram-based scores, and their survival differences were assessed using CIF curves.RESULTS: The 3-year and 5-year cumulative mortalities were 49.6 and 55.8% for LC-SM and 8.2 and 11.8% for OCSM, respectively. In multivariate analysis, increasing age, male sex, no surgery, and advanced T, N and M stages were related to a significantly higher likelihood of LC-SM. The nomogram showed good calibration, and the 3-year and 5-year C-indexes for predicting the probabilities of LC-SM in the validation cohort were both 0.79, which were almost equal to those of the ten-fold cross validation. DCA demonstrated that using the nomogram gained more benefit when the threshold probabilities were set within the ranges of 0.24-0.89 and 0.25-0.91 for 3-year and 5-year LCSM, respectively. In both the training and validation cohorts, the high-risk group had the highest probabilities of LC-SM, followed by the medium-risk and low-risk groups (both P < 0.0001).CONCLUSIONS: The competing risk nomogram displayed excellent discrimination and calibration for predicting LC-SM. With the aid of this individualized predictive tool, clinicians can more expediently devise appropriate treatment protocols and follow-up schedules.",
author = "Xiao Wu and Wenfeng Yu and Petersen, {R. H.} and Hongxu Sheng and Yiqing Wang and Wang Lv and Jian Hu",
year = "2020",
doi = "10.1186/s12885-020-06927-w",
language = "English",
volume = "20",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma

AU - Wu, Xiao

AU - Yu, Wenfeng

AU - Petersen, R. H.

AU - Sheng, Hongxu

AU - Wang, Yiqing

AU - Lv, Wang

AU - Hu, Jian

PY - 2020

Y1 - 2020

N2 - BACKGROUND: Adenosquamous carcinoma (ASC) is an uncommon histological subtype of lung cancer. The purpose of this study was to assess the cumulative incidences of lung cancer-specific mortality (LC-SM) and other cause-specific mortality (OCSM) in lung ASC patients, and construct a corresponding competing risk nomogram for LC-SM.METHODS: Data on 2705 patients with first primary lung ASC histologically diagnosed between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The cumulative incidence function (CIF) was utilized to calculate the 3-year and 5-year probabilities of LC-SM and OCSM, and a competing risk model was built. Based on the model, we developed a competing risk nomogram to predict the 3-year and 5-year cumulative probabilities of LC-SM and the corresponding concordance indexes (C-indexes) and calibration curves were derived to assess the model performance. To evaluate the clinical usefulness of the nomogram, decision curve analysis (DCA) was conducted. Furthermore, patients were categorized into three groups according to the tertile values of the nomogram-based scores, and their survival differences were assessed using CIF curves.RESULTS: The 3-year and 5-year cumulative mortalities were 49.6 and 55.8% for LC-SM and 8.2 and 11.8% for OCSM, respectively. In multivariate analysis, increasing age, male sex, no surgery, and advanced T, N and M stages were related to a significantly higher likelihood of LC-SM. The nomogram showed good calibration, and the 3-year and 5-year C-indexes for predicting the probabilities of LC-SM in the validation cohort were both 0.79, which were almost equal to those of the ten-fold cross validation. DCA demonstrated that using the nomogram gained more benefit when the threshold probabilities were set within the ranges of 0.24-0.89 and 0.25-0.91 for 3-year and 5-year LCSM, respectively. In both the training and validation cohorts, the high-risk group had the highest probabilities of LC-SM, followed by the medium-risk and low-risk groups (both P < 0.0001).CONCLUSIONS: The competing risk nomogram displayed excellent discrimination and calibration for predicting LC-SM. With the aid of this individualized predictive tool, clinicians can more expediently devise appropriate treatment protocols and follow-up schedules.

AB - BACKGROUND: Adenosquamous carcinoma (ASC) is an uncommon histological subtype of lung cancer. The purpose of this study was to assess the cumulative incidences of lung cancer-specific mortality (LC-SM) and other cause-specific mortality (OCSM) in lung ASC patients, and construct a corresponding competing risk nomogram for LC-SM.METHODS: Data on 2705 patients with first primary lung ASC histologically diagnosed between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The cumulative incidence function (CIF) was utilized to calculate the 3-year and 5-year probabilities of LC-SM and OCSM, and a competing risk model was built. Based on the model, we developed a competing risk nomogram to predict the 3-year and 5-year cumulative probabilities of LC-SM and the corresponding concordance indexes (C-indexes) and calibration curves were derived to assess the model performance. To evaluate the clinical usefulness of the nomogram, decision curve analysis (DCA) was conducted. Furthermore, patients were categorized into three groups according to the tertile values of the nomogram-based scores, and their survival differences were assessed using CIF curves.RESULTS: The 3-year and 5-year cumulative mortalities were 49.6 and 55.8% for LC-SM and 8.2 and 11.8% for OCSM, respectively. In multivariate analysis, increasing age, male sex, no surgery, and advanced T, N and M stages were related to a significantly higher likelihood of LC-SM. The nomogram showed good calibration, and the 3-year and 5-year C-indexes for predicting the probabilities of LC-SM in the validation cohort were both 0.79, which were almost equal to those of the ten-fold cross validation. DCA demonstrated that using the nomogram gained more benefit when the threshold probabilities were set within the ranges of 0.24-0.89 and 0.25-0.91 for 3-year and 5-year LCSM, respectively. In both the training and validation cohorts, the high-risk group had the highest probabilities of LC-SM, followed by the medium-risk and low-risk groups (both P < 0.0001).CONCLUSIONS: The competing risk nomogram displayed excellent discrimination and calibration for predicting LC-SM. With the aid of this individualized predictive tool, clinicians can more expediently devise appropriate treatment protocols and follow-up schedules.

U2 - 10.1186/s12885-020-06927-w

DO - 10.1186/s12885-020-06927-w

M3 - Journal article

C2 - 32416716

VL - 20

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

M1 - 429

ER -

ID: 241943890